{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2026-02-13T12:36:32.704730+00:00",
  "news": [
    {
      "title": "Amgen wins new EU approval for Uplizna in gMG - European Pharmaceutical Review",
      "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQNVdrSkFRb01GOW9CVmRQakg5dFh6aW5GWEFJWmY1NnBhUzIyVXVKejFkU0daLTBuSHBnWUpQOC1QaHdwd1dEMjE1enlxQ2djS2dseFRZVlZSVkpBVFhRS0hiTXJTUGxFbUkxa0RUWWJrVXpBRHNIVEVORW1OU05kWDJpYU1BRl9iZWN3MkdkQk5CLU9oSnRCVkt1eUwta280MlJGcEQzWWdnUERKS2xRamlDQUMwTWlEZWZj?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQNVdrSkFRb01GOW9CVmRQakg5dFh6aW5GWEFJWmY1NnBhUzIyVXVKejFkU0daLTBuSHBnWUpQOC1QaHdwd1dEMjE1enlxQ2djS2dseFRZVlZSVkpBVFhRS0hiTXJTUGxFbUkxa0RUWWJrVXpBRHNIVEVORW1OU05kWDJpYU1BRl9iZWN3MkdkQk5CLU9oSnRCVkt1eUwta280MlJGcEQzWWdnUERKS2xRamlDQUMwTWlEZWZj?oc=5\" target=\"_blank\">Amgen wins new EU approval for Uplizna in gMG</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">European Pharmaceutical Review</font>",
      "published": "2026-02-13T12:16:10+00:00",
      "source": "European Pharmaceutical Review"
    },
    {
      "title": "LSV Asset Management Raises Holdings in Amgen Inc. $AMGN - MarketBeat",
      "link": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPR0NTR1FHMFJkbHRhVkFBcGRfb1Y4NWJPWHFLanBZc2F1TldfTUZFNGhZaDBGVThjWGNXeHd4c1dLdkpiektMRjZYa251alpyNmpjelBQdndxNlFRY0pJaUJuTkh0SlhoaFJVZ3FUal9jaWF0dUlPVDZuOGJPUUdDeXBOdXZvdTFUUHAwSFRmeHNyWk81aEhOODBCSEc0alM2MGd2VW9hbEM5Sm1xRHMzZTh4TWEwdw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMitgFBVV95cUxPR0NTR1FHMFJkbHRhVkFBcGRfb1Y4NWJPWHFLanBZc2F1TldfTUZFNGhZaDBGVThjWGNXeHd4c1dLdkpiektMRjZYa251alpyNmpjelBQdndxNlFRY0pJaUJuTkh0SlhoaFJVZ3FUal9jaWF0dUlPVDZuOGJPUUdDeXBOdXZvdTFUUHAwSFRmeHNyWk81aEhOODBCSEc0alM2MGd2VW9hbEM5Sm1xRHMzZTh4TWEwdw?oc=5\" target=\"_blank\">LSV Asset Management Raises Holdings in Amgen Inc. $AMGN</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MarketBeat</font>",
      "published": "2026-02-13T11:34:25+00:00",
      "source": "MarketBeat"
    },
    {
      "title": "Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPQlBxZHVZbU9ldkc0N1hCQ1dJbEZyb3FERTVvY3hZVWtaWWNBNTJjUURwM2RxNmE4TVBtVjJyWWNQU3pQT2NaSTFlUWNQdWhSUHNhclI4TVVZZm15SFE1QUlLTlVWdGViM3A1aGhJbGFFZnh1UkhqVXhnbVZKY1hLUldQQWZkMGM?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihwFBVV95cUxPQlBxZHVZbU9ldkc0N1hCQ1dJbEZyb3FERTVvY3hZVWtaWWNBNTJjUURwM2RxNmE4TVBtVjJyWWNQU3pQT2NaSTFlUWNQdWhSUHNhclI4TVVZZm15SFE1QUlLTlVWdGViM3A1aGhJbGFFZnh1UkhqVXhnbVZKY1hLUldQQWZkMGM?oc=5\" target=\"_blank\">Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2026-02-13T01:14:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "UPLIZNA’s Expanded EU Use in Autoimmune Disease Could Be A Game Changer For Amgen (AMGN) - simplywall.st",
      "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxON2xMMWRvdmpadkV0WGdiZmFqN0VHY2lUcEh3QTU4X09lam5CNmpUVHNRS1hBRGRzX2I1NkdMNUlVTXMtZEdQdk9CSEZ5bW9GYVNwVXJvOEdnOFN2SG5jcG80ZVRLTXF1X0dtLVgxUzdVTnczXzhVbHBXc1B5YzJGVzVGUVhMTVpNelVBdG9MTW5Xa09vVlZnZkxKWEJDeTQyNTA1MGwtaUxHdFlZcENrTEJqOUYybUhHRlhjVjg1TEhTT2JLNVNIZkxhSkVNRXhjYjFxaTBB?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxON2xMMWRvdmpadkV0WGdiZmFqN0VHY2lUcEh3QTU4X09lam5CNmpUVHNRS1hBRGRzX2I1NkdMNUlVTXMtZEdQdk9CSEZ5bW9GYVNwVXJvOEdnOFN2SG5jcG80ZVRLTXF1X0dtLVgxUzdVTnczXzhVbHBXc1B5YzJGVzVGUVhMTVpNelVBdG9MTW5Xa09vVlZnZkxKWEJDeTQyNTA1MGwtaUxHdFlZcENrTEJqOUYybUhHRlhjVjg1TEhTT2JLNVNIZkxhSkVNRXhjYjFxaTBB?oc=5\" target=\"_blank\">UPLIZNA’s Expanded EU Use in Autoimmune Disease Could Be A Game Changer For Amgen (AMGN)</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2026-02-13T04:54:27+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "Freedom Capital Markets downgrades Amgen stock rating to Hold from Buy - Investing.com",
      "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPZEhZbkMwSDE5MG1SRlVabTVieV9rZXJtMXZPbV9vazZoQUo5Wl9Qb2l0X0NtNDgwY3MxVWlxMnZhRXJkRzVYMTA5Nkk5QnpyUlFmeXFzcmNkVUJiUDJBQWJfZGltd210a2c0SldjYjlLVE9Gdmh4cVhZU0F2dE93cVNJcEpyeXR4UHAtMW80Zm5rZkxPRndSVEpZWHQyNEZYNTZ5azZVMVhwR3I5MWdfWmdWVjliM0lUcGlIU1JINDRhX0J2WndPN3ZB?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiygFBVV95cUxPZEhZbkMwSDE5MG1SRlVabTVieV9rZXJtMXZPbV9vazZoQUo5Wl9Qb2l0X0NtNDgwY3MxVWlxMnZhRXJkRzVYMTA5Nkk5QnpyUlFmeXFzcmNkVUJiUDJBQWJfZGltd210a2c0SldjYjlLVE9Gdmh4cVhZU0F2dE93cVNJcEpyeXR4UHAtMW80Zm5rZkxPRndSVEpZWHQyNEZYNTZ5azZVMVhwR3I5MWdfWmdWVjliM0lUcGlIU1JINDRhX0J2WndPN3ZB?oc=5\" target=\"_blank\">Freedom Capital Markets downgrades Amgen stock rating to Hold from Buy</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing.com</font>",
      "published": "2026-02-12T22:01:08+00:00",
      "source": "Investing.com"
    },
    {
      "title": "Amgen receives EC approval for Uplizna in gMG - Pharmaceutical Business review -",
      "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPOEZuWlZoVWhWYzVUZXNPdy10UUtDVlM1Skd2U2RtNFRYaTlRNi1LcHZzdVhKd2JKWlFNU3ZGSkRGZDN3a3h5SmUxYWxMWElQOEdlX0NwZE1vZXB0V2tnaWs2UC1MTWU4ZVhZQ0V5M3Q2anpMOFpmdmFHNW1XZEo0YUxBUmVhYWRyNmc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiigFBVV95cUxPOEZuWlZoVWhWYzVUZXNPdy10UUtDVlM1Skd2U2RtNFRYaTlRNi1LcHZzdVhKd2JKWlFNU3ZGSkRGZDN3a3h5SmUxYWxMWElQOEdlX0NwZE1vZXB0V2tnaWs2UC1MTWU4ZVhZQ0V5M3Q2anpMOFpmdmFHNW1XZEo0YUxBUmVhYWRyNmc?oc=5\" target=\"_blank\">Amgen receives EC approval for Uplizna in gMG</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Pharmaceutical Business review -</font>",
      "published": "2026-02-13T11:07:57+00:00",
      "source": "Pharmaceutical Business review -"
    },
    {
      "title": "Amgen wins EC approval for Uplizna in gMG - The Pharma Letter",
      "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNbDQtTjZNZXY5NU5mYVNpNWNKbkdfNFYxaGJ1XzBEOU5XallIamlhcHp5V1JlTG1NTFlBVGVmODVhckRWdjFMOE1sRTEzZEkzbWlGbFRxNU00eXVVOWRaYUZsVkU0M2ZUanZjVGtxWl9IX0g3aFFxVU82aHVtcVE1NFptQ1pWeThYM0RoeTBwdw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMijwFBVV95cUxNbDQtTjZNZXY5NU5mYVNpNWNKbkdfNFYxaGJ1XzBEOU5XallIamlhcHp5V1JlTG1NTFlBVGVmODVhckRWdjFMOE1sRTEzZEkzbWlGbFRxNU00eXVVOWRaYUZsVkU0M2ZUanZjVGtxWl9IX0g3aFFxVU82aHVtcVE1NFptQ1pWeThYM0RoeTBwdw?oc=5\" target=\"_blank\">Amgen wins EC approval for Uplizna in gMG</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Pharma Letter</font>",
      "published": "2026-02-12T17:08:21+00:00",
      "source": "The Pharma Letter"
    },
    {
      "title": "EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS - PR Newswire",
      "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOdVpUcXM2WWpfT1FoZWFWcVViTVM3TWROY01VdWF0OVlsS0RYWWZmbzZiY2NiZHVsOXNSVHhMdE9vZzlvYk5kRmxpZlBOaHFRNWxjMWttd0JTenRoUVVRUzRzMGlOUEFVeVJJNU45QnlmdzREbHJzcFc5c2pKS1l4LUJ1d201eU8yclM4aE5WQXBnLVltbjh0WHZ0UnVqdXJGVGNXcmxuaWFlN3JBTmtWUDBrdEdnVXVtY0hBN19lQjB5MFkzZG5aYnl0cXpuQQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMizgFBVV95cUxOdVpUcXM2WWpfT1FoZWFWcVViTVM3TWROY01VdWF0OVlsS0RYWWZmbzZiY2NiZHVsOXNSVHhMdE9vZzlvYk5kRmxpZlBOaHFRNWxjMWttd0JTenRoUVVRUzRzMGlOUEFVeVJJNU45QnlmdzREbHJzcFc5c2pKS1l4LUJ1d201eU8yclM4aE5WQXBnLVltbjh0WHZ0UnVqdXJGVGNXcmxuaWFlN3JBTmtWUDBrdEdnVXVtY0hBN19lQjB5MFkzZG5aYnl0cXpuQQ?oc=5\" target=\"_blank\">EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PR Newswire</font>",
      "published": "2026-02-12T14:00:00+00:00",
      "source": "PR Newswire"
    }
  ],
  "product_launches": [
    {
      "title": "Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating - TipRanks",
      "link": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNOGRMMXF5YlJsZk83RlJqN3ozY1VjSUlkYnpXX05zZmZCWnRoRHNrTk9IdGVYczVZVk9WTkw0MjNKYmkySWZXOUdDdGFXZWRrRjR6U0VSbmtJbkx6NkQ1bkQycGxEWDlZRVdSTzJidFBabTZLOWxkWnI0WktQMXRNX1lCS04xMmFhV3lrV1BDbGRmRlVhSnBfV1BaMmoyc3hTV3lZOTBRX08tRnRuX0hKTkplc05sN1Q2enYxSDE4X2ZkcFVVU1lENks1VUJHWFZzY2tfOUIxaFBEa1dnRkQw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNOGRMMXF5YlJsZk83RlJqN3ozY1VjSUlkYnpXX05zZmZCWnRoRHNrTk9IdGVYczVZVk9WTkw0MjNKYmkySWZXOUdDdGFXZWRrRjR6U0VSbmtJbkx6NkQ1bkQycGxEWDlZRVdSTzJidFBabTZLOWxkWnI0WktQMXRNX1lCS04xMmFhV3lrV1BDbGRmRlVhSnBfV1BaMmoyc3hTV3lZOTBRX08tRnRuX0hKTkplc05sN1Q2enYxSDE4X2ZkcFVVU1lENks1VUJHWFZzY2tfOUIxaFBEa1dnRkQw?oc=5\" target=\"_blank\">Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>",
      "published": "2026-02-04T03:18:16+00:00",
      "source": "TipRanks"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-16T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "3 major patent losses this year — and a key strategy to fill the gaps - PharmaVoice",
      "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5\" target=\"_blank\">3 major patent losses this year — and a key strategy to fill the gaps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PharmaVoice</font>",
      "published": "2025-07-21T07:00:00+00:00",
      "source": "PharmaVoice"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach - simplywall.st",
      "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNLXhOdjVpSkxmUXdQRVpHS2tPVUdGcG1EZHJFZDZpNzg5Y3pCT3FTdlVhNFR4MmhicGVQN0luNnNVMkZCOTF5NkR0WWlUOXVtMmtfbzBJWVE4dUlwbjFXX29sREp3enhLVkowNV9QbXd4UGtMTlJjd29PSHNPSUd3TkhJNm55T1AxRTdUazNkd0NHRThWMGtTZU44V3lidnR5UmQyMWZxd0FrcHVPTVlfWTJWQTFMTGRQRDZQcEtaSlc0TklGNzlMam1pRjhDVVVpc0ZRSg?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNLXhOdjVpSkxmUXdQRVpHS2tPVUdGcG1EZHJFZDZpNzg5Y3pCT3FTdlVhNFR4MmhicGVQN0luNnNVMkZCOTF5NkR0WWlUOXVtMmtfbzBJWVE4dUlwbjFXX29sREp3enhLVkowNV9QbXd4UGtMTlJjd29PSHNPSUd3TkhJNm55T1AxRTdUazNkd0NHRThWMGtTZU44V3lidnR5UmQyMWZxd0FrcHVPTVlfWTJWQTFMTGRQRDZQcEtaSlc0TklGNzlMam1pRjhDVVVpc0ZRSg?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2025-09-08T07:00:00+00:00",
      "source": "simplywall.st"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2026-02-12",
      "close": 366.20001220703125
    },
    "history": [
      {
        "date": "2026-02-04",
        "close": 366.20001220703125
      },
      {
        "date": "2026-02-05",
        "close": 367.79998779296875
      },
      {
        "date": "2026-02-06",
        "close": 384.32000732421875
      },
      {
        "date": "2026-02-09",
        "close": 375.82000732421875
      },
      {
        "date": "2026-02-10",
        "close": 364.6499938964844
      },
      {
        "date": "2026-02-11",
        "close": 366.5799865722656
      },
      {
        "date": "2026-02-12",
        "close": 366.20001220703125
      }
    ],
    "name": "Amgen Inc."
  }
}